Skip to content

US · GLSI · BIOTECHNOLOGY

Greenwich LifeSciences, Inc. (GLSI) intrinsic value and stock valuation

$19.25as of 2026-11-21 · Mkt cap 210.78M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Greenwich LifeSciences, Inc. DCF and intrinsic value

InvestorsCraft values GLSI with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from GLSI’s statements →

Greenwich LifeSciences, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Stafford, TX 77477 greenwichlifesciences.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$0.00
20172025
Net income
-$-19.36M
20172025
Free cash flow
-$-9.91M
20172025
Total equity
$350K-58.3% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-19.45M-$-17.64M-$-9.33M-$-8.04M-$-4.6M
Net income-$-19.36M-$-17.41M-$-8.89M-$-7.83M-$-4.57M
EPSd-$-1.43M-$-1.34M-$-691.83K-$-606.51K-$-353.17K
Operating cash flow-$-9.91M-$-7.27M-$-6.48M-$-6.2M-$-4.29M
Capital expenditure$0.00$0.00$0.00-$0.00$0.00
Free cash flow-$-9.91M-$-7.27M-$-6.48M-$-6.2M-$-4.29M
Total assets$6.18M$4.09M$6.99M$13.5M$27.2M
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-6.18M-$-4.09M-$-6.99M-$-13.47M-$-27.2M
Total equity$350K$2.53M$6.7M$13.2M$26.8M
Cash and short-term investments$6.18M$4.09M$6.99M$13.5M$27.2M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit-$0.00-$0.00-$0.00-$0.00-$0.00
Research and development expenses$17.2M$15.5M$7.7M$6.48M$3.56M
Selling, general and administrative expenses$2.23M$2.15M$1.63M$1.56M$1.04M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$19.5M$17.6M$9.32M$8.04M$4.59M
Cost and expenses$19.5M$17.6M$9.33M$8.04M$4.6M
Interest income$90K$220K$440K$220K$30K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Ebitda-$-19.36M-$-17.41M-$-8.89M-$-7.82M-$-4.57M
Operating income-$-19.45M-$-17.64M-$-9.33M-$-8.04M-$-4.6M
Total other income/expenses, net$90K$220K$440K$220K$30K
Income before tax-$-19.36M-$-17.41M-$-8.89M-$-7.83M-$-4.57M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-19.36M-$-17.41M-$-8.89M-$-7.83M-$-4.57M
Weighted average shares outstanding$13.5M$13M$12.9M$12.9M$12.9M
Weighted average diluted shares outstanding$13.5M$13M$12.9M$12.9M$12.9M
Balance sheet
20252024202320222021
Cash and short-term investments$6.18M$4.09M$6.99M$13.5M$27.2M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$6.18M$4.09M$6.99M$13.5M$27.2M
Property, plant and equipment, net$0.00$0.00$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$10K$10K$10K
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$0.00$0.00$10K$10K$10K
Total assets$6.18M$4.09M$6.99M$13.5M$27.2M
Accounts payable$4.87M$1.18M$40K$220K$220K
Short-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$5.82M$1.56M$290K$260K$390K
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00$0.00$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$5.82M$1.56M$290K$260K$390K
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-87.14M-$-66.15M-$-50.36M-$-41.47M-$-33.65M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00-$0.00
Total equity$350K$2.53M$6.7M$13.2M$26.8M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-6.18M-$-4.09M-$-6.99M-$-13.47M-$-27.2M
Cash flow statement
20252024202320222021
Net income-$-19.36M-$-15.79M-$-8.89M-$-7.83M-$-4.57M
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Stock-based compensation$6.8M$7.25M$2.38M$1.74M$660K
Change in working capital$2.64M$1.27M$30K-$-120K-$-390K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$2.07M$920K$40K$0.00-$-530K
Net cash provided by operating activities-$-9.91M-$-7.27M-$-6.48M-$-6.2M-$-4.29M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$0.00$0.00$0.00
Common stock issued$12M$4.37M$0.00$0.00$3.11M
Common stock repurchased$0.00$0.00$0.00-$-7.54M$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$12M$4.37M$0.00-$-7.54M$2.84M
Net change in cash$2.09M-$-2.9M-$-6.48M-$-13.74M-$-1.46M
Cash at end of period$6.18M$4.09M$6.99M$13.5M$27.2M
Operating cash flow-$-9.91M-$-7.27M-$-6.48M-$-6.2M-$-4.29M
Capital expenditure$0.00$0.00$0.00-$0.00$0.00
Free cash flow-$-9.91M-$-7.27M-$-6.48M-$-6.2M-$-4.29M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Greenwich LifeSciences, Inc.

        Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.

        CEO
        Snehal S. Patel
        Employees
        13
        Beta
        1.39

        Explore

        Frequently asked questions

        What is the intrinsic value of Greenwich LifeSciences, Inc. (GLSI)?

        InvestorsCraft does not currently publish an intrinsic value for GLSI. How the IC value is calculated.

        Is GLSI undervalued?

        InvestorsCraft does not publish an undervaluation signal for GLSI at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.